Advertisement
BIO vs FLGT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongBuy and FLGT is a Buy.
BIO in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026
The 10-day moving average for BIO crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BIO as a result. In 69 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for BIO just turned positive on October 23, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.
BIO moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
BIO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.422) is normal, around the industry mean (4.142). P/E Ratio (46.363) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for FLGT turns positive, indicating new upward trend
FLGT saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned positive. In 56 of the 75 cases, the stock moved higher in the following days. The odds of a move higher are at 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for FLGT just turned positive on November 06, 2026. Looking at past instances where FLGT's MACD turned positive, the stock continued to rise in 30 of 48 cases over the following month. The odds of a continued upward trend are 62%.
FLGT moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for FLGT crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +40.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where FLGT advanced for three days, in 188 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FLGT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
FLGT broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for FLGT entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.652) is normal, around the industry mean (67.298). P/E Ratio (-8.389) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.013) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. FLGT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FLGT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
BIO | FLGT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 93 | |
PRICE GROWTH RATING 1..100 | 15 | 37 | |
P/E GROWTH RATING 1..100 | 2 | 73 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FLGT's Valuation (36) in the Medical Or Nursing Services industry is somewhat better than the same rating for BIO (90) in the Medical Specialties industry. This means that FLGT’s stock grew somewhat faster than BIO’s over the last 12 months.
FLGT's Profit vs Risk Rating (100) in the Medical Or Nursing Services industry is in the same range as BIO (100) in the Medical Specialties industry. This means that FLGT’s stock grew similarly to BIO’s over the last 12 months.
BIO's SMR Rating (87) in the Medical Specialties industry is in the same range as FLGT (93) in the Medical Or Nursing Services industry. This means that BIO’s stock grew similarly to FLGT’s over the last 12 months.
BIO's Price Growth Rating (15) in the Medical Specialties industry is in the same range as FLGT (37) in the Medical Or Nursing Services industry. This means that BIO’s stock grew similarly to FLGT’s over the last 12 months.
BIO's P/E Growth Rating (2) in the Medical Specialties industry is significantly better than the same rating for FLGT (73) in the Medical Or Nursing Services industry. This means that BIO’s stock grew significantly faster than FLGT’s over the last 12 months.
| BIO | FLGT | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 59% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 75% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 69% |
| TrendMonth ODDS (%) | 1 day ago 69% | 1 day ago 69% |
| Advances ODDS (%) | 3 days ago 65% | 3 days ago 68% |
| Declines ODDS (%) | 1 day ago 69% | 1 day ago 77% |
| BollingerBands ODDS (%) | 1 day ago 70% | 1 day ago 73% |
| Aroon ODDS (%) | 1 day ago 68% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 2 FA rating(s) are green while FLGT’s FA Score has 0 green FA rating(s).
- BIO’s FA Score: 2 green, 3 red.
- FLGT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 5 TA indicator(s) are bullish while FLGT’s TA Score has 5 bullish TA indicator(s).
- BIO’s TA Score: 5 bullish, 4 bearish.
- FLGT’s TA Score: 5 bullish, 5 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +3.09% price change this week, while FLGT (@Medical Specialties) price change was +33.09% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.92%. For the same industry, the average monthly price growth was -5.08%, and the average quarterly price growth was +38.31%.
Reported Earning Dates
BIO is expected to report earnings on Feb 18, 2027.
FLGT is expected to report earnings on Feb 26, 2027.
Industries' Descriptions
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-4.92% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
FLGT and
Correlation & Price change
A.I.dvisor indicates that over the last year, FLGT has been loosely correlated with CERS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if FLGT jumps, then CERS could also see price increases.
| Ticker / NAME | Correlation To FLGT | 1D Price Change % | ||
|---|---|---|---|---|
| FLGT | 100% | -0.31% | ||
| CERS - FLGT | 40% Loosely correlated | +8.72% | ||
| BIO - FLGT | 39% Loosely correlated | -0.12% | ||
| NVST - FLGT | 38% Loosely correlated | -2.01% | ||
| MXCT - FLGT | 38% Loosely correlated | -2.65% | ||
| CLPT - FLGT | 37% Loosely correlated | +4.56% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| OILU | 47.62 | 2.60 | +5.78% |
| MicroSectors Oil & Gas Exp. & Prod. 3x Leveraged ETN (OILU) | |||
| FAI | 50.72 | 1.35 | +2.73% |
| First Trust Exchange-Traded Fund II | |||
| JHEM | 37.64 | 0.69 | +1.87% |
| John Hancock Multifactor Emerging Markets ETF (JHEM) | |||
| UUPP | 25.17 | N/A | N/A |
| Principal CLO ETF (UUPP) | |||
| VCSH | 77.47 | -0.07 | -0.09% |
| Vanguard Short-Term Corporate Bond ETF (VCSH) | |||